Related Experiment Video
Updated: May 2, 2026
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Inflammatory markers from routine blood tests predict survival in multiple myeloma: a Systematic Review and
Mengjiao Luo1, Ling Qin1, Yujie Li1
1Department of Clinical Laboratory, Ningbo Medical Center Lihuili Hospital, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China.
Background:
Multiple myeloma (MM) is an incurable hematologic malignancy marked by abnormal plasma cell proliferation. Inflammatory indices derived from routine blood tests-such as neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), red cell distribution width (RDW), RDW-to-platelet ratio (RPR), and hemoglobin-to-RDW ratio (HRR)-have shown prognostic value across cancers. This meta-analysis aimed to evaluate their prognostic significance in MM.
Methods:
Following PRISMA guidelines, a systematic search of PubMed, Embase, and Web of Science identified eligible studies through January 17, 2025. Pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Sensitivity and subgroup analyses were conducted to assess heterogeneity, and publication bias was evaluated using Egger's and Begg's tests.
Results:
Twenty-seven studies including 5,009 MM patients were analyzed. Elevated NLR was significantly associated with poor overall survival (OS: HR = 2.06, 95% CI: 1.72-2.47) and progression-free survival (PFS: HR = 1.70, 95% CI: 1.32-2.19), as well as advanced disease stage (OR = 2.85, 95% CI: 1.40-5.80). High RDW and low LMR were similarly linked to worse outcomes (RDW-OS: HR = 1.68; LMR-OS: HR = 0.58). PLR showed no significant association with prognosis. RPR and HRR results were inconsistent due to limited data.
Conclusion:
NLR, LMR, and RDW are promising prognostic biomarkers in MM, with elevated NLR and RDW and decreased LMR indicating poorer outcomes. PLR, RPR, and HRR require further investigation. These routinely accessible indices may aid in clinical risk stratification and therapeutic decision-making.
Systematic Review Registration:
https://www.crd.york.ac.uk/PROSPERO/view/CRD420251105106, identifier CRD420251105106.
More Related Videos
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
